Interleukin-4 secretion by the allograft fails to affect the allograft- specific interleukin-4 response in vitro

Transplantation

Volumn 67, Issue 12, 1999, Pages 1583-1589

  Davies, Joanna D ^a   Mueller, Regula ^a   Minson, Susan ^a   O'Connor, Eric ^a   Krahl, Troy ^a   Sarvetnick, Nora ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR;

ALLOGRAFT; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOKINE RELEASE; GRAFT REJECTION; MOUSE; NONHUMAN; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SPLEEN CELL; TRANSGENE;

ANIMALS; EPITOPES; GRAFT REJECTION; INTERLEUKIN-2; INTERLEUKIN-4; MICE; MICE, INBRED C57BL; MICE, SCID; MICE, TRANSGENIC; PANCREAS TRANSPLANTATION; SPLEEN; TRANSGENES; TRANSPLANTATION, HOMOLOGOUS;

EID: 0032976418     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199906270-00013     Document Type: Article

References (48)

1. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348.
2. Sher A, Coffman RL. Regulation of immunity to parasites by T cells and T cell-derived cytokines. Annu Rev Immunol 1992; 10: 385.
3. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787.
4. Romagnani S. Human Th1 and Th2 subsets: doubt no more. Immunol Today 1991; 12: 256.
5. Hseih C-S, Heimberger AB, Gold JS, O'Garra A, Murphy K. Differential regulation of T helper phenotype development by IL-4 and IL-10 in an ab-transgenic system. Proc Natl Acad Sci USA 1992; 89: 6065.
6. Le Gros G, Ben-Sasson S, Seder R, Finkelman FD, Paul WE. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J Exp Med 1990; 172: 921.
7. Swain SL, Weinberg AD, English M, Huston G. IL-4 directs the development of Th2-like helper effectors. J Immunol 1990; 145: 3796.
8. + T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260: 547.
9. + T cells from T cell receptor transgenic mice. J Exp Med 1992; 176: 1091.
10. + T cells to enhance priming for interferon γ production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA 1993; 90: 10188.
11. Manetti R, Parronchi P, Guidizi MG, et al. Natural killer cell stimulatory factor interleukin 12 (IL-12) induces T helper type (Th1)-specific immune responses and inhibits the development of IL-4-producing cells. J Exp Med 1993; 177: 1199.
12. O'Connell PJ, Pacheco-Silva A, Nickerson PW, et al. Unmodified pancreatic islet allograft rejection results in the preferential expression of certain T cell activation transcripts. J Immunol 1993; 150: 1093.
13. Dallman MJ, Larsen CP, Morris PJ. Cytokine gene transcription in vascularised organ grafts: analysis using semiquantitative polymerase chain reaction. J Exp Med 1991; 174: 493.
14. Dallman MJ. Cytokines as mediators of organ graft rejection and tolerance. Curr Opin Immunol 1993; 5: 788.
15. Nickerson P, Steurer W, Steiger J, Zheng X, Steele AW, Strom TB. Cytokines and the Th1/Th2 paradigm in transplantation. Curr Opin Immunol 1994; 6: 757-64.
16. Takeuchi T, Lowry RP, Konieczny B. Heart allografts in murine systems: the differential activation of Th2-like effector cells in peripheral tolerance. Transplantation 1992; 53: 1281.
17. Dallman MJ, Shiho O, Page TH, Wood KJ, Morris PJ. Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway. J Exp Med 1991; 173: 79.
18. Sayegh MH, Akalin E, Hancock WW, et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995; 181: 1869.
19. Hancock WW, Sayegh MH, Kwok CA, Weiner HL, Carpenter CB. Oral, but not intravenous, alloantigen prevents accelerated allograft rejection by selective intragraft Th2 cell activation. Transplantation 1993; 55: 1112.
20. Kupiec-Weglinski JW, Wasowska B, Papp I, et al. CD4 mAb therapy modulates alloantibody production and intracardiac graft deposition in association with selective inhibition of Th1 lymphokines. J Immunol 1993; 151: 5053.
21. Nickerson P, Pacheco-Silva A, O'Connell PJ, Steurer W, Kelley VR, Strom TB. Analysis of cytokine transcripts in pancreatic islet cell allografts during rejection and tolerance induction. Transplant Proc 1993; 25: 984.
22. Bugeon L, Cuturi MC, Hallet MM, Paineau J, Chabannes D, Soulillou JP. Peripheral tolerance of an allograft in adult rats -characterization by low interleukin-2 and interferon-gamma mRNA levels and by strong accumulation of major histocompatibility complex transcripts in the graft. Transplantation 1992; 54: 219.
23. Binder J, Lehmann M, Graser E, et al. The effects of non-depleting CD4 targeted therapy in presensitized rat recipients of cardiac allografts. Transplantation 1996; 61: 804.
24. Mottram PL, Han WR, Purcell LJ, McKenzie IF, Hancock WW. Increased expression of IL-4 and IL-10 and decreased expression of IL-2 and interferon-gamma in long-surviving mouse heart allografts after brief CD4-monoclonal antibody therapy. Transplantation 1995; 59: 559.
25. Vossen ACTM, Tibbe GJM, Benner R, Savelkoul HFJ. T-lymphocyte and cytokine-directed strategies for inhibiting skin allograft rejection in mice. Transplant Proc 1995; 27: 380.
26. Maliszewski CR, Morrisey PJ, Fanslow WC, Sato TA, Willis C, Davidcon B. Delayed allograft rejection in mice transgenic for a soluble form of the IL-4-receptor. Cell Immunol 1992; 143: 434.
27. Fanslow WC, Clifford KN, Park LS, et al. Regulation of alloreactivity in vivo by IL-4 and the soluble IL-4 receptor. J Immunol 1991; 147: 535.
28. VanBuskirk A, Wakely ME, Orosz CG. Transfusion of polarized Th2-like cell populations into seid mouse cardiac allograft recipients results in acute allograft rejection. Transplantation 1996; 62: 229.
29. Maeda H, Takata M, Takahashi S, Ogoshi S, Fujimoto S. Adoptive transfer of a Th2-like cell line prolongs MHC class II antigen disparate skin allograft survival in the mouse. Int Immunol 1994; 6: 855.
30. Mueller R, Davies JD, Krahl T, Sarvetnick N. IL-4 expression by grafts from transgenic mice fails to prevent allograft rejection. J Immunol 1997; 159: 1599.
31. Mueller R, Krahl T, Sarvetnick N. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 1996; 184: 1093.
32. Mueller R, Krahl T, Sarvetnick N. Tissue-specific expression of interleukin-4 induces extracellular matrix accumulation and extravasation of B cells. Lab Invest 1997; 76: 117.
33. - helper cells that secrete interleukin 2 (IL-2), IL-3, IL-4 and interferon γ. J Exp Med 1991; 174: 547.
34. Swain SL, Dennert G, Warner J, Dutton RW. Culture supernatants of a stimulated T cell line have helper activity that acts synergistically with interleukin-2 in the response of B cells to antigen. Proc Natl Acad Sci USA 1981; 78: 2517.
35. Kirkman RL, Barrett LV, Gaulton GN, Kelley VE, Ythier A, Strom TB. Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med 1985; 162: 358.
36. Tellides G, Dallman MJ, Morris PJ. Mechanism of action of interleukin-2 receptor (IL-2R) monoclonal antibody (Mab) therapy: Target cell depletion or inhibition of function? Transplant Proc 1989; 21: 997.
37. Kupiec-Weglinski JW, Diamantstein T, Tilney NL. Interleukin 2 receptor-targeted therapy-rationale and application in organ transplantation. Transplantation 1988; 46: 785.
38. Steiger J, Nickerson PW, Steurer W, Moscovitch-Lopatin M, Strom TB. IL-2 knockout recipient mice reject islet cell allografts. J Immunol 1995; 155: 489.
39. Konieczny BT, Saleem S, Lowry RP, Lakkis FG. Vigorous allograft rejection in IFN gamma gene knockout mice [Abstract]. In: Proceedings of the 15th Annual Meeting of the American Society of Transplant Physicians. New Jersey: Slack Publishers, 1996: 170.
40. Piccoti JR, Chan SY, Goodman RE, Magram J, Eichwald EJ, Bishop DK. IL-12 antagonism induces Th2 responses, yet exacerbates cardiac allograft rejection: evidence against a dominant protective role for Th2 cytokines in alloimmunity. J Immunol 1996; 157: 1951.
41. Chan SY, DeRruyne LA, Goodman RE, Eichwald EJ, Bishop DK. In vivo depletion of CD8+ T cells results in Th2 cytokine production and alternate mechanisms of allograft rejection. Transplantation 1995; 59: 1155.
42. Lowry RP, Konieczny B, Alexander D, et al. Interleukin-10 enhances anti-CD3 monoclonal antibody-induced mortality and prolongs heart allograft survival in inbred mice. Transplant Proc 1995; 27: 392.
43. Zheng XX, Steele AW, Nickerson PW, Steurer W, Steiger J, Strom TB. Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J Immunol 1995; 154: 5590.
44. Takeuchi T, Ueki T, Sunaga S, et al. Murine interleukin 4 transgenic heart allograft survival prolonged with down-regulation of the Th1 cytokine mRNA in grafts. Transplantation 1997; 64: 152.
45. Siegling A, Lehmann M, Riedel H, et al. A non-depleting anti-rat CD4 monoclonal antibody that suppresses T helper 1-like but not T helper 2-like intragraft lymphokine secretion induces long-term survival of renal allografts. Transplantation 1994; 57: 464.
46. + T cells in vivo. Differential expression of IL-2 and IL-4 mRNA in recipients of cardiac allografts. J Immunol 1992; 148: 1308.
47. Lehmann M, Graser E, Risch K, et al. Anti-CD4 monoclonal antibody induced allograft tolerance in rats despite persistence of donor reactive T cells. Transplantation 1997; 64: 1181.
48. Qin L, Chavin KD, Ding Y, et al. Multiple vectors effectively achieve gene transfer in a murine cardiac transplantation model. Immunosuppression with TGFb1 or IL-10. Transplantation 1995; 59: 809.